person · Reporting owner
Steenvoorden Lawrence J.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHEMBIO DIAGNOSTICS, INC.
Report date January 05, 2023 · Filed May 01, 2023
Section 16 reporting ended · disclosed 2023-05-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-04-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2023-01-05 · Exercise / conversion · Acquired 53,571 · Balance 53,571 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2023-01-05 · Tax withholding · Disposed 16,118 · Balance 37,453 F2: These shares were withheld for tax purposes upon the vesting of restricted stock units. Row 3 · 2023-04-26 · Other · Disposed 37,453 · Balance 0 F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 107,143 |
Reported balance
After 2023-01-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-05 · Exercise / conversion · Disposed 53,571 · Balance 107,143 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F4: On January 5, 2022, the reporting person was granted 160,714 restricted stock units which vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-27 · Disposition to issuer · Disposed 107,143 · Balance 0 F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F5: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). |
| Nonqualified stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-01-05 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-04-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F6: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: These shares were withheld for tax purposes upon the vesting of restricted stock units.
F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F4: On January 5, 2022, the reporting person was granted 160,714 restricted stock units which vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person).
F5: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement).
F6: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor.
CareCloud, Inc.
Report date January 17, 2024 · Filed January 04, 2025
Section 16 reporting ended · disclosed 2025-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-17 · Disposition to issuer · Disposed 61,549 · Balance 0 F1: Each restricted stock unit represents the right to receive, at settlement and upon vesting, one share of common stock. F2: On January 17, 2024, the restricted stock unit was cancelled by mutual agreement of the reporting person and the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, at settlement and upon vesting, one share of common stock.
F2: On January 17, 2024, the restricted stock unit was cancelled by mutual agreement of the reporting person and the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2024 Filed Jan 4, 2025 02:30 UTC | CareCloud, Inc. CCLD · Entity 6780 | Disposition to issuerRestricted Stock Unit · Derivative | 61,549 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-000341 · ownership.xml · derivative · entry 1 Steenvoorden Lawrence J. · CIK 0001902795 · No longer an employee 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,549 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement and upon vesting, one share of common stock. F1 · price: Each restricted stock unit represents the right to receive, at settlement and upon vesting, one share of common stock. F2 · derivative.exercise_date: On January 17, 2024, the restricted stock unit was cancelled by mutual agreement of the reporting person and the issuer. F2 · derivative.expiration_date: On January 17, 2024, the restricted stock unit was cancelled by mutual agreement of the reporting person and the issuer. Read SEC document |
| August 10, 2023 Filed Aug 12, 2023 01:30 UTC | CareCloud, Inc. CCLD · Entity 6780 | Exercise / conversionRestricted Stock Unit · Derivative | 17,097 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027927 · ownership.xml · derivative · entry 3 Steenvoorden Lawrence J. · CIK 0001902795 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,549 Underlying: Common Stock · 17,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the conversion upon vesting of restricted stock units into common stock on August 10, 2023. These restricted stock units and the shares of common stock issued upon vesting of such units were acquired under the Company's Amended and Restated Equity Incentive Plan, without payment by the reporting person. The remaining restricted stock units vest between July 2024 and July 2026. F1 · price: Represents the conversion upon vesting of restricted stock units into common stock on August 10, 2023. These restricted stock units and the shares of common stock issued upon vesting of such units were acquired under the Company's Amended and Restated Equity Incentive Plan, without payment by the reporting person. The remaining restricted stock units vest between July 2024 and July 2026. F1 · derivative.exercise_date: Represents the conversion upon vesting of restricted stock units into common stock on August 10, 2023. These restricted stock units and the shares of common stock issued upon vesting of such units were acquired under the Company's Amended and Restated Equity Incentive Plan, without payment by the reporting person. The remaining restricted stock units vest between July 2024 and July 2026. F1 · derivative.expiration_date: Represents the conversion upon vesting of restricted stock units into common stock on August 10, 2023. These restricted stock units and the shares of common stock issued upon vesting of such units were acquired under the Company's Amended and Restated Equity Incentive Plan, without payment by the reporting person. The remaining restricted stock units vest between July 2024 and July 2026. Read SEC document |
| August 10, 2023 Filed Aug 12, 2023 01:30 UTC | CareCloud, Inc. CCLD · Entity 6780 | Tax withholdingCommon Stock | 5,984 | $2.17 | $12,985.28 |
DisclosureSEC source: 0001493152-23-027927 · ownership.xml · nonDerivative · entry 2 Steenvoorden Lawrence J. · CIK 0001902795 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,113 F2 · kind: Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon awarding of the common stock. This is not an open market sale of securities. Read SEC document |
| August 10, 2023 Filed Aug 12, 2023 01:30 UTC | CareCloud, Inc. CCLD · Entity 6780 | Exercise / conversionCommon Stock | 17,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027927 · ownership.xml · nonDerivative · entry 1 Steenvoorden Lawrence J. · CIK 0001902795 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the conversion upon vesting of restricted stock units into common stock on August 10, 2023. These restricted stock units and the shares of common stock issued upon vesting of such units were acquired under the Company's Amended and Restated Equity Incentive Plan, without payment by the reporting person. The remaining restricted stock units vest between July 2024 and July 2026. Read SEC document |
| April 27, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | Disposition to issuerNonqualified stock options · Derivative | 300,000 | Not disclosed Strike: $1.12 | Not disclosed |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · derivative · entry 6 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 300,000 shares Expires 2029-01-05 F6 · kind: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. F6 · price: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. F6 · derivative.exercise_date: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Read SEC document |
| April 27, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | Disposition to issuerRestricted stock units · Derivative | 107,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · derivative · entry 5 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 107,143 shares Expires not disclosed F3 · derivative.exercise_price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F5 · kind: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). F5 · price: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). F5 · derivative.exercise_date: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). F5 · derivative.expiration_date: Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). Read SEC document |
| April 26, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | OtherCommon Stock | 37,453 | $0.45 | $16,853.85 |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · nonDerivative · entry 3 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F3 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document |
| January 05, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | Exercise / conversionRestricted stock units · Derivative | 53,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · derivative · entry 4 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,143 Underlying: Common stock · 53,571 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On January 5, 2022, the reporting person was granted 160,714 restricted stock units which vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). F4 · derivative.expiration_date: On January 5, 2022, the reporting person was granted 160,714 restricted stock units which vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). Read SEC document |
| January 05, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | Tax withholdingCommon Stock | 16,118 | $0.25 | $4,029.50 |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · nonDerivative · entry 2 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,453 F2 · kind: These shares were withheld for tax purposes upon the vesting of restricted stock units. Read SEC document |
| January 05, 2023 Filed May 1, 2023 21:03 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | Exercise / conversionCommon Stock | 53,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-022238 · form4.xml · nonDerivative · entry 1 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 21:00 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | GrantNonqualified stock options · Derivative | 300,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001140361-22-000875 · form4.xml · derivative · entry 2 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common stock · 300,000 shares Expires 2029-01-05 F3 · derivative.exercise_date: The nonqualified stock options are scheduled to vest in four equal installments on January 5, 2023, 2024, 2025 and 2026, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person's employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 21:00 UTC | CHEMBIO DIAGNOSTICS, INC. CEMI · Entity 114014 | GrantRestricted stock units · Derivative | 160,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-000875 · form4.xml · derivative · entry 1 Steenvoorden Lawrence J. · CIK 0001902795 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,714 Underlying: Common stock · 160,714 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock F2 · derivative.exercise_date: The restricted stock units are scheduled to vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). F2 · derivative.expiration_date: The restricted stock units are scheduled to vest in three equal installments on January 5, 2023, 2024 and 2025, provided they shall vest in full immediately prior to (a) the issuer's termination of the reporting person employment without Cause, the reporting person's termination of his employment for Good Reason or the expiration of the Term upon notice of nonrenewal delivered by the Company, in each case within twelve months following a Change in Control, or (b) the reporting person's death or Permanent Disability (each such capitalized term as defined in the employment agreement between the issuer and the reporting person). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.